Company intelligence / Profile preview

VLP The Vaccines Company

Gaithersburg, Maryland, United States

Ownership: Private
Development stage: Other

Overview

VLP Therapeutics develops cancer treatment vaccines and prophylactic vaccines against infectious diseases. The company's proprietary i-αVLP vaccine technology platform aims to create breakthrough treatments. VLPT Japan is developing COVID-19 vaccines using replicon (next-generation mRNA) technology.

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccinemRNA-based vaccine
Industry: Biotech

Partnerships

Sojitz CorporationU.S. ArmyWHOmajor pharmaceutical company (CRADA agreement)Japan Agency for Medical Research and Development (AMED)Japanese Ministry of Health, Labour and WelfareJapanese Ministry of Economy Trade and Industry

Beyond the preview

Go deeper on VLP The Vaccines Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VLP The Vaccines Company.

Explore the full profile